

Contents

Foreword	v
List of Tables and Figures	xi
VIVIANE QUIRKE AND JUDY SLINN	
Perspectives on Twentieth-Century Pharmaceuticals: an introduction	1
PART 1 Different Countries, Times and Perspectives	
35	
JONATHAN SIMON AND AXEL C. HÜNTELMANN	
1 Two Models for Production and Regulation: the diphtheria serum in Germany and France	37
FRANK HUISMAN	
2 Struggling for the Market: strategies of Dutch pharmaceutical companies, 1880–1940	63
MARÍA JESÚS SANTESMASES	
3 Distributing Penicillin: the clinic, the hero and industrial production in Spain, 1943–1952	91
PART 2 Different Actors: scientists, doctors and patients	
119	
MARION A. HULVERSCHEIDT	
4 The Scientist-Entrepreneur or Financing in Pharmaceutical Research: a portrait of the malariologist Werner Schulemann, 1888–1975	121

CAY-RÜDIGER PRÜLL

- 5 Scientists, Doctors and Drug Development: the history
of Raymond P. Ahlquist's receptor theory, 1948–1988 149

CLAUDE RICHARD AND MARIE-THERESE LUSSIER

- 6 Proposition of a Model for the Discussion of Medications
during Medical Encounters 185

PART 3 Developing, Selling and Representing Drugs 215

TONY CORLEY

- 7 Twentieth-Century American Contributions
to the Growth of the Beecham Enterprise 217

SERGIO SISMONDO

- 8 Linking Research and Marketing,
a Pharmaceutical Innovation 241

MANON NIQUETTE AND WILLIAM J. BUXTON

- 9 Relieving Twentieth-Century Excesses: the socialization of
antacid and laxative uses through advertising 257

PART 4 Drug Regulation and its Limits in the United States 283

JOHN P. SWANN

- 10 Reducing with Dinitrophenol: self-medication and the
challenge of regulating a dangerous pharmaceutical before
the US Food, Drug, and Cosmetic Act 285

DOMINIQUE A. TOBBELL

- 11 Charitable Innovations: the political economy of
thalassemia research and drug development in the
United States, 1960–2000 303

HEATHER MUNRO PRESCOTT

- 12 Imperfect Methods and Uncertain Choices:
the regulation and marketing of emergency contraception
in the United States 339

PART 5 From Pharma to Biotech 365

BEAT BÄCHI

- 13 Producing Ascorbic Acid: how microbes transformed the
pharmaceutical company Hoffmann-la Roche, 1933–1953 367

MICHAEL BÜRGI AND BRUNO J. STRASSER

- 14 Pharma in Transition: new approaches to drug development
at F. Hoffmann-la Roche & Co, 1960–1980 393

ANNE-LAURE SAIVES, MEHRAN EBRAHIMI AND ROBERT H. DESMARTEAU,

WITH THE COLLABORATION OF CATHERINE GARNIER

- 15 Knowledge Creation Dynamics and the Growth of
Biotech Firms in Quebec 435

Notes on Contributors 467

Index 475